跳至主要内容
临床试验/NCT00906438
NCT00906438已完成1 期

Effects of 2006-RD-05 on Salivary and Serum IgA Levels in Healthy Subjects

innoVactiv Inc.2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2009年5月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
50
试验地点
2
主要终点
Occurrence of adverse events

研究概览

简要总结

It is already known from animal studies that the study drug can improve mucosal immunity as shown by increased serum and mucosal IgA secretion. This study will evaluate the safety of an oral intake of the natural product 2006-RD-05 at the recommended daily dose of 300 mg. In addition, this trial will aim to determine if this intake is able ot improve serum and salivary IgA synthesis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Men or women aged 18 - 60
  • In good health
  • BMI between 20 and 30 kg/m2
  • Non-smoking

排除标准

  • Allergic to study drug
  • Use of immune-modulating drugs
  • Uncontrolled hypertension (Systolic > 140 or diastolic > 90)
  • Women of childbearing age not using proper contraception, that is pregnant or breastfeeding

结局指标

主要结局

Occurrence of adverse events

时间窗: Baseline, 14 days, 28 days

次要结局

  • Serum IgA titers(Baseline, 14 days, 28 days)
  • Salivary IgA titers(Baseline, 14 days, 28 days)

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验